Abstract

Mitozantrone (Novantrone - Lederle) is a new cytotoxic drug licensed for the treatment of breast cancer, hepatocellular carcinoma, non-Hodgkin lymphomas and relapsed acute myeloblastic leukaemia in adults. The manufacturer calls it “the key to new opportunities in cancer chemotherapy” with less toxicity than related drugs. Does the evidence support this?